Sanofi Consumer Healthcare India Limited has submitted its Annual Secretarial Compliance Report for the financial year ended 31st December 2025 to the stock exchanges, fulfilling its regulatory obligations under SEBI guidelines. The company filed the mandatory report with both BSE Limited and National Stock Exchange of India Limited on 1st March 2026, demonstrating its commitment to corporate governance and regulatory compliance.

Regulatory Compliance Overview

The Annual Secretarial Compliance Report was prepared by BNP & Associates, Company Secretaries, covering the company's adherence to statutory provisions and corporate governance practices. The comprehensive review examined the company's compliance with various SEBI regulations and guidelines throughout the financial year 2025.

Key Regulatory Areas Examined

The secretarial audit covered multiple critical areas of regulatory compliance. BNP & Associates examined the company's adherence to Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The company maintained a Structured Digital Database as required under the insider trading regulations.

Additionally, the review encompassed compliance with Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, along with associated circulars and guidelines.

Comprehensive Compliance Assessment

The secretarial compliance report evaluated 13 specific areas of regulatory requirements, with the company achieving full compliance across all parameters. Key areas of assessment included performance evaluation of the Board and Independent Directors, related party transaction approvals, and timely disclosure of events under Regulation 30.

Clean Compliance Record

The report confirmed that no violations or deviations were identified during the review period. The company maintained a clean record with no actions taken by SEBI or stock exchanges against the entity, its promoters, or directors. No statutory auditor resignations occurred during the financial year, and no additional non-compliances were observed beyond those reported.

Corporate Structure and Operations

Sanofi Consumer Healthcare India Limited operates with its registered office at Unit 1104, 11th Floor, Godrej Two, Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai, Maharashtra. As a subsidiary of a company incorporated outside India, the entity follows a calendar year as its financial year to facilitate consolidation with its holding company, having obtained requisite approval under Section 2(41) of the Companies Act, 2013.

The company secretary and compliance officer, Nikunj Kumar Savaliya, digitally signed and submitted the compliance report, ensuring proper documentation and regulatory adherence. The comprehensive assessment by BNP & Associates validates the company's robust compliance framework and commitment to regulatory excellence throughout the financial year 2025.

Sanofi Consumer Healthcare India Limited has announced robust financial results for the quarter and year ended December 31, 2025, demonstrating strong operational performance across key metrics. The company published its audited financial results in Business Standard and Sakal newspapers on February 27, 2026.

Strong Quarterly Performance

The company delivered exceptional growth in Q4 FY25, with significant improvements across all major financial parameters. The quarterly results showcase the company's ability to maintain momentum in a competitive healthcare market.

Annual Financial Highlights

For the full financial year FY25, Sanofi Consumer Healthcare India maintained its growth trajectory with consistent performance improvements. The annual results reflect the company's strategic initiatives and market positioning in the consumer healthcare segment.

Sequential Quarter Performance

Comparing Q4 FY25 with the previous quarter (Q3 FY25), the company showed continued momentum with total income increasing from ₹2,369 million to ₹2,556 million, representing a 7.89% sequential growth. Net profit after tax also improved from ₹629 million in Q3 FY25 to ₹665 million in Q4 FY25.

Dividend Recommendation and Corporate Actions

The Board of Directors has recommended a final dividend of ₹75 per equity share of ₹10 face value for the year ended December 31, 2025. This dividend recommendation is subject to approval by shareholders at the upcoming Annual General Meeting.

Regulatory Compliance and Governance

The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) and were reviewed by the Audit Committee before approval by the Board of Directors on February 25, 2026. The company maintains its commitment to transparency and regulatory compliance under SEBI listing requirements.